DEX-0249

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Total Pages in this Submission

Docket No.

TO THE ASSISTANT COMMISSIONER FOR PATENTS

Box Patent Application Washington, D.C. 20231

Washington, D.C. 20231									
Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application for an									
invention entitled: COMPOSITIONS AND METHODS RELATING TO BREAST SPECIFIC GENES AND PROTEINS									
and invented by:									
Sun et al.									
If a CONTINUATION APPLICATION, check appropriate box and supply the requisite information:									
☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.:									
Which is a:									
☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.:									
Which is a: Continuation Divisional Continuation-in-part (CIP) of prior application No.:									
Continuation — Divisional — Continuation in part (oil)— of prior application view									
Enclosed are:									
Application Elements									
1. 🛛 Filing fee as calculated and transmitted as described below									
2. Specification having pages and including the following:									
a. 🗵 Descriptive Title of the Invention									
b. 🗵 Cross References to Related Applications (if applicable)									
c. Statement Regarding Federally-sponsored Research/Development (if applicable)									
d. Reference to Microfiche Appendix (if applicable)									
e. 🗵 Background of the Invention									
f. 🛛 Brief Summary of the Invention									
g. Brief Description of the Drawings (if drawings filed)									
h. Detailed Description									
i. 🛛 Claim(s) as Classified Below									
j. 🛮 Abstract of the Disclosure									

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. DEX-0249

Total Pages in this Submission

Application Elements (Continued)											
3.		Drawing(s) (when necessary as prescribed by 35 USC 113)									
	a.		Formal Number of Sheets								
	b.		Informal Number of Sheets								
4.	X	Oath or Declaration									
	a.	Newly executed (original or copy)									
	b.	Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional application only)									
	C.	c. 🛛 With Power of Attorney 🔲 Without Power of Attorney									
	d.	 DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. 1.63(d)(2) and 1.33(b). 									
5.		Incorporation By Reference (usable if Box 4b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.									
6.		Con	Computer Program in Microfiche (Appendix)								
7.	×	Nucleotide and/or Amino Acid Sequence Submission (if applicable, all must be included)									
	a.	Paper Copy									
	b.	\boxtimes	Computer Readable Copy (identical to computer copy)								
	c. 🗵 Statement Verifying Identical Paper and Computer Readable Copy										
			Accompanying Application Parts								
₽.		Ass	ignment Papers (cover sheet & document(s))								
9.		37 (CFR 3.73(B) Statement (when there is an assignee)								
10.		English Translation Document (if applicable)									
11.		Information Disclosure Statement/PTO-1449 Copies of IDS Citations									
12.		Preliminary Amendment									
13.	×	Acknowledgment postcard									
14.	X	Certificate of Mailing									
		☐ First Class ☒ Express Mail (Specify Label No.): EL859835090US									

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. DEX-0249

Total Pages in this Submission

Accompanying Application Parts (Continued)										
15.		Certified Copy of Priority Document(s) (if foreign priority is claimed)								
16.		Additional Enclosures (please identify below):								
17.		Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2) Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application.								
		Warning								
		An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), must notify the Director of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice was unintentional.								
•										
•										

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. DEX-0249

Total Pages in this Submission

Fee Calculation and Transmittal

CLAIMS AS FILED For #Filed #Allowed #Extra Rate Fee \$0.00 **Total Claims** 19 - 20 = 0 \$18.00 х \$0.00 Indep. Claims 2 - 3 = 0 \$84.00 х \$280.00 Multiple Dependent Claims (check if applicable) \boxtimes \$740.00 **BASIC FEE** \$0.00 OTHER FEE (specify purpose) **TOTAL FILING FEE** \$1,020.00

J	A check in the amount of			to cover the filing fee is enclosed.					
X	The Co	mmissioner is hereby aut	horized to cha	rge and credit Depo	sit Account N	o. 50-1619			
	as desc	cribed below. A duplicate	copy of this s	heet is enclosed.					
	\boxtimes	Charge the amount of	\$1,020.00	as filing fee.					
•	\boxtimes	Credit any overpayment.							
	☑ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17.								
		Charge the issue fee set	in 37 C.F.R.	1.18 at the mailing o	of the Notice of	f Allowance,			
		pursuant to 37 C.F.R. 1.3	311(b).		/ 1	10 ,1			
				97	ather !	V. /birch			
						76.V 1 V 1			

Signature

Kathleen A. Tyrrell, Registration No. 38,350

Licata & Tyrrell P.C. 66 East Main Street Marlton, N.J. 08053 Tel: 856-810-1515 Fax: 856-810-1454

cc:

Dated: October 29, 2001

DEX-0249

CERTIFICATE OF EXPRESS MAILING

"Express Mail" Label No. **EL859835090US** Date of Deposit: **October 29, 2001**

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R 1.10 on the date indicated above and is addressed to the "BOX SEQUENCE", Assistant Commissioner for Patents, Washington, D.C. 20231.

- 1) Patent Application Transmittal Letter (2 copies);
- 2) Application consisting of 157 pages of Specification, including three (3) pages of Claims and one (1) page of Abstract;
- Return Postcard;
- 4) Authorization to charge deposit account \$1,020.00;
- 5) Unexecuted Declaration and Power of Attorney;
- 6) Statement to Support Filing and Submission in Accordance with 37 C.F.R. §§1.821-1.825;
- 7) Sequence listing; and
- 8) Diskette containing computer readable copy of Sequence Listing.

Hathler A Juvel KATHLEEN A. TYRRELL

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.:

DEX-0249

Inventors:

Sun et al.

Serial No.:

Not yet assigned

Filing Date:

Herewith

Examiner:

Not yet assigned

Group Art Unit:

Not yet assigned

Title:

Compositions and Methods Relating to Breast Specific Genes and Proteins

"Express Mail" Label No. EL859835090US Date of Deposit - October 29, 2001

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for

Patents, Washington, D.C. 20231.

By Allen A. Tyrrell, Registration No.38,350

BOX SEQUENCE

Assistant Commissioner for Patents Washington, DC 20231

Sir:

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE WITH 37 CFR §§ 1.821 THROUGH 1.825

- (XX) I hereby state, in accordance with the requirements of 37 C.F.R. §1.821(f), that the contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR §1.821(c) and (e), respectively are the same.
- () I hereby state that the submission filed in accordance with 37 CFR §1.821(g) does not include new matter.

- () I hereby state that the submission filed in accordance with 37 CFR §1.821(h) does not include new matter or go beyond the disclosure in the international application as filed.
- () I hereby state that the amendments, made in accordance with 37 CFR §1.825(a), included in the substitute sheet(s) of the Sequence Listing were made to conform with the current Sequence Listing rules. I hereby state that the substitute sheet(s) of the Sequence Listing does not include new matter.
- () I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR §1.825(b), is the same as the amended Sequence Listing.
- () I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR §1.825(d), contains identical data to that originally filed.

Respectfully submitted,

Dathler A. Livel

Kathleen A. Tyrrely

Registration No. 38,350

Date: October 29, 2001

Licata & Tyrrell P.C. 66 E. Main Street Marlton, New Jersey 08053

(856) 810-1515